An Adaptive Phase I Intra-Patient Dose Escalation Study Of Fenretinide In Adult Cystic Fibrosis Patients
The proposed research project is a Phase 1 clinical trial looking at the safety of fenretinide, a molecule based on the structure of vitamin A, on patients with a disease called cystic fibrosis. Fenretinide has been shown in our laboratory to help cystic fibrosis mice by lowering molecules involved in inflammation and increasing the levels of docosahexaenoic acid (DHA), which is a fatty acid known to decrease inflammation. The intern will be involved in patient sample processing, analyzing and logging. She will also work with Laurent Pharmaceuticals to develop protocols for Phase 2a trials and the documentation needed for regulatory agencies such as the Investigators Brochure.